Catalyst Wire Dossier Catalyst Wire Dossier

Xeligekimab

· Chongqing Genrix Biopharmaceutical Co., Ltd
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Xeligekimab, covering 2025-01-31 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis [Phase 4]

See pricing